Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

3 Small-Cap Stocks That Fall Short

February 04, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

3 Cash-Producing Stocks That Concern Us

February 01, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also...

3 Healthcare Stocks We Steer Clear Of

January 29, 2026

Topics Stocks

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

January 28, 2026

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

January 27, 2026

Amneal has been on fire lately. In the past six months alone, the company’s stock price has rocketed 63.3%, reaching $13.34 per share. This was partly thanks to its solid quarterly results, and the...

2 Reasons to Sell AMRX and 1 Stock to Buy Instead

January 25, 2026

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

December 22, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

1 Small-Cap Stock to Target This Week and 2 That Underwhelm

December 17, 2025

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

December 09, 2025

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

December 05, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,...

3 Healthcare Stocks We’re Skeptical Of

December 02, 2025

Represents second complex respiratory therapeutic product approval in Q4 2025

Topics Stocks

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

December 02, 2025

Amneal to Participate in Upcoming Investor Conferences

December 02, 2025

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

December 01, 2025

Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? ↗

November 28, 2025

The pharmaceutical company has experienced sales growth over the past five years.

Via The Motley Fool

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

One executive’s option-linked sale may look large on paper, but the broader context tells a more nuanced story.

Topics Economy

Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs ↗

November 21, 2025

Via The Motley Fool

Topics Regulatory Compliance

Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks

November 19, 2025

Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Topics Artificial Intelligence Intellectual Property

3 Russell 2000 Stocks with Warning Signs

November 13, 2025

First-to-market complex injectable with expected launch in Q1 2026

Amneal Receives U.S. FDA Approval for Iohexol Injection

November 13, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

3 Stocks Under $50 We Steer Clear Of

November 11, 2025

Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Topics Artificial Intelligence Stocks

3 Value Stocks We Find Risky

November 09, 2025

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations...

Why Amneal (AMRX) Stock Is Up Today

October 31, 2025

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗

October 30, 2025

Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS.

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars

October 30, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s...

Amneal Reports Third Quarter 2025 Financial Results

October 30, 2025

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

October 29, 2025

Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment